AFFECTING 5.1 MILLION
Alzheimer’s disease (AD) ranks as one of the toughest nuts to crack within drug discovery and development. Current treatments merely manage symptoms, so finding a better solution becomes more and more urgent as the aging population grows.
Approximately 70 percent of dementia cases are caused by AD. It is a neurodegenerative disorder— neurons progressively lose structure and function. As the disease continues and more neurons are damaged and die, symptoms get worse. Neurons in the hippocampal region of the brain associated with memory formation are among the first affected. By 2025, the number of people age 65 and older with AD is projected to reach 7.1 million—a 40 percent increase from the 5.1 million affected in 2015 (Alzheimer’s Association).
A number of different companies are working to develop treatments, with a few already in clinical trials. In this two-part series, we’ll first explain what is known about the molecular causes of AD, then explore Alzheimer’s drugs that are in development.
PLAQUES AND TANGLES
Alzheimer’s disease is associated with the build-up of amyloid-beta (Aβ) plaques in patients’ brains. But what, exactly, are Aβ plaques? Aβ plaques derive from the cleavage of a protein called the amyloid precursor protein, which is thought to play a role in the formation of synapses. Individual Aβ molecules clump together to form the plaques associated with Alzheimer’s.
Until recently, the mechanism by which Aβ plaques might cause Alzheimer’s was not known. Recent research from Stanford University suggests the plaques bind to a receptor on nerve cells, disrupting their function. However, there is no absolute consensus on whether these clumps of protein are the origins of AD or a symptom of the underlying cause.
Another brain protein associated with Alzheimer’s is tau, which is concentrated in the neurons and is primarily understood as a component in stabilizing nerve cell structure. Abnormal aggregates of tau form “tangles” within nerve cells. These tangles are correlated with the onset of Alzheimer’s along with the characteristic plaque formations.
GENETICS PLAYS A ROLE
About 70% of Alzheimer’s cases are thought to have at least some genetic association, with different genes being implicated depending on the type of Alzheimer’s.
A gene found on chromosome 19 called the apolipoprotein E gene (APOE) influences the development of late-onset Alzheimer’s. Individuals with different variants of the APOE gene have different risk profiles:
- Variant ε2 (APOE2) is rare and possibly lessens or delays Alzheimer’s onset
- Variant ε3 (APOE3) is neutral
- Variant ε4 (APOE4) is associated with a significantly increased risk of Alzheimer’s
The APOE proteins plays a role in clearing Aβ from the brain, with APOE4 carrying out this function less efficiently than the other variants. There is also some evidence that APOE4 contributes to the breakdown of the blood-brain barrier seen in patients, resulting in increased brain inflammation—another marker of Alzheimer’s. A better understanding of APOE4’s role in Alzheimer’s onset may lead to the development of a whole new class of drug.
IF AT FIRST YOU DON’T SUCCEED…
A number of drug developers have attempted to use monoclonal antibodies (mAbs) to disrupt the formation of the AD-associated Aβ plaques. Unfortunately, this approach has yet to experience clinical success. However, this doesn’t mean that the approach is not viable – different mAbs attach to different parts of Aβ, meaning that the outcome of one mAb trial does not necessarily predict the outcome of another. Biogen (Cambridge, MA) and Roche (Basel, Switzerland) both have mAb therapies targeting Aβ plaques in Phase III clinical development. In earlier phase studies, these mAbs showed the most promise in patients with less advanced forms of the disease.
The prevention of Aβ plaques is also the focus of growing interest in creating an AD vaccine. Leading this effort is Novartis (Basel, Switzerland), whose CAD106 vaccine contains fragments of the Aβ protein and has been shown to be safe in Phase I trials. The goal of the vaccine is to activate an immune response against Aβ, thereby reducing its accumulation and potential to form plaques in the brain. CAD106 is currently in Phase II/III studies of efficacy, in which the vaccine is being tested in cognitively normal individuals between the ages of 60 and 70 who are at high risk of developing the disease based on their APOE4 status.
AbbVie (North Chicago, IL) is targeting tau, the other major protein associated with AD. The company currently has an anti-tau mAb therapy in Phase II clinical testing, and last month announced a partnership with Voyager Therapeutics (Cambridge, MA) to develop a gene therapy treatment that targets tau. The treatment will deliver a gene encoding an anti-tau antibody directly to cells in patients’ brains – enabling those cells to make the antibody. If successful, this would bypass altogether the blood-brain barrier that makes it difficult for some drugs to even enter the brain.
Amyloid-beta and tau remain tantalizing targets for AD drug development because of their close association with the disease. However, new approaches are springing up as frustration over the lack of progress in treating this devastating disease grows. Stay tuned for the next Weekly, where we will describe some of these new approaches.
Emily Burke, PhD has worked in biopharma for 20 years, gaining science writing experience at The Scripps Research Institute and Ionis Pharmaceuticals. As a Ph.D. molecular biologist, she is passionate about advancing the public’s understanding of science. In addition to being a self-proclaimed “science geek,” she is regularly asked to speak at international scientific meetings. When not teaching and writing the WEEKLY for Biotech Primer, Dr. Burke swims with her swim club and performs regularly on the improv circuit in San Diego.